TAS 205

Drug Profile

TAS 205

Alternative Names: TAS-205

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator Taiho Pharmaceutical
  • Class
  • Mechanism of Action Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Duchenne muscular dystrophy

Most Recent Events

  • 01 May 2016 Phase-II clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Japan (PO) (NCT02752048 and Otsuka Pharmaceuticals pipeline, September 2016)
  • 21 Apr 2016 Taiho Pharmaceutical plans a phase IIa trial for Duchenne muscular dystrophy (In adolescents, In children, In adults) in Japan (PO) (NCT02752048)
  • 30 Sep 2014 Phase-I clinical trials in Duchenne muscular dystrophy (In adolescents, In children) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top